Cost-effectiveness of stroke treatments and secondary preventions

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 12, 2012, Pages 1751-1760

  Pan, Feng ^a   Hernandez, Luis ^a   Ward, Alex ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Acute stroke treatment; Cost effectiveness; Economic models; Economics; Pharmacoeconomics; Secondary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; AUSTRALIA; BLOOD CLOT LYSIS; CANADA; CARDIOEMBOLIC STROKE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DENMARK; DISABILITY; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EMERGENCY CARE; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; RECURRENT DISEASE; REHABILITATION CARE; REVIEW; SECONDARY PREVENTION; SPAIN; STROKE; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; WORK CAPACITY;

COST-BENEFIT ANALYSIS; HEMATOLOGIC AGENTS; HUMANS; SECONDARY PREVENTION; STROKE;

EID: 84864034788     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.699522     Document Type: Review

References (47)

1. Demaerschalk B, Hwang H, Leung G. US cost burden of ischemic stroke: A systematic literature review. Am J Manag Care 2010;16(7):525-533
2. Mackay J, Mensah GA. World health organization. the atlas of heart disease and stroke. 2004.Available from: Http://www.who.int/cardiovascular- diseases/en/cvd-atlas-15-burden-stroke.pdf [Last accessed 11 August 2011]
3. Heart and Stroke Foundation. Stroke statistics. 2011.Available from: Http://www.heartandstroke.com/site/c. ikIQLcMWJtE/b.3483991/k.34A8/Statistics. htm [Last accessed 8 August 2011]
4. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: A report from the American heart association. Circulation 2011;123:e18-e209
5. Furie K, Kasner S, Adams R, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2011;42:227-276
6. National Collaborating Centre for Chronic Conditions. Stroke: National clinical guideline for diagnosis and initial management of acute stroke and transient ischaemic attack (TIA). Royal College of Physicians; London: 2008
7. Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: A review and summary of challenges. Value Health 2009;12:507-520
8. Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011;377(9778):1681-1692
9. Sinclair SE, Frighetto L, Loewen PS, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: A Canadian healthcare perspective. Pharmacoeconomics 2001;19:927-936
10. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 2002;5:82-97
11. Moodie ML, Carter R, Mihalopoulos C, et al. Trial application of a model of resource utilization, costs, and outcomes for stroke (MORUCOS) to assist priority setting in stroke. Stroke 2004;35:1041-1046
12. Sandercock P, Berge E, Dennis M, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004;35:1490-1497
13. Mihalopoulos C, Cadilhac DA, Moodie ML, et al. Development and application of model of resource utilization, costs, and outcomes for stroke (MORUCOS): An Australian economic model for stroke. Int J Technol Assess Health Care 2005;21:499-505
14. Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 2005;20:193-200
15. Ehlers L, Andersen G, Clausen LB, et al. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 2007;38:85-89
16. Johnston SC. The economic case for new stroke thrombolytics. Stroke 2010;41:S59-62
17. Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke 2006;37:2751-2758
18. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 2005;36(11):2500-2503
19. Demaerschalk BM. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada. Stroke 2007;38(6):1952-1955
20. Burn J. The outcome of a first stroke: The Oxford community stroke project [MD thesis]. 1991.Available from: Www. nip.dk [Last accessed 19 July 2011]
21. Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke 1994;25:1721-1725
22. Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998;50:883-890
23. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998;29:1083-1091
24. Ringleb PA, Schwark C, Schwaninger M, Schellinger PD. Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke. Expert Opin Pharmacother 2005;6:359-367
25. Kirshner H. Secondary stroke prevention and management: An evidence-based update for managed care: An examination of guideline-recommended treatment strategies for optimal individualized care and improvement of outcomes in the prevention of secondary stroke. 2008.Available from: Http://www. cecentral.com/assets/1419/xen09028-content-FINAL.pdf [Last accessed 28 January 2012]
26. Heeg B, Damen J, Van Hout B. Oral antiplatelet therapy in secondary prevention of cardiovascular events: An assessment from the payer's perspective. Pharmacoeconomics 2007;25:1063-1082
27. Beard SM, Gaffney L, Bamber L, De Platchett J. Economic modelling of antiplatelet therapy in the secondary prevention of stroke. J Med Econ 2004;7:117-134
28. Jones L, Griffin S, Palmer S, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: A systematic review and economic evaluation. Health Technol Assess 2004;8:iii-v; 1-196
29. Karnon J, Brennan A, Pandor A, et al. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin 2005;21:101-112
30. Marissal JP, Selke B. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France. Pharmacoeconomics 2004;22:661-670
31. Matchar DB, Samsa GP, Liu S. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: The limits of certainty. Value Health 2005;8:572-580
32. Sarasin FP, Gaspoz JM, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000;160:2773-2778
33. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: A cost-effectiveness analysis. Am J Med 2004;116:797-806
34. Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysis. Clin Ther 2000;22:362-370
35. Kongnakorn T, Ward A, Roberts CS, et al. Economic valuation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health 2009;12(6):880-887
36. Desbiens NA. Deciding on anticoagulating the oldest old with atrial fibrillation: Insights from cost-effectiveness analysis. J Am Geriatr Soc 2002;50:863-869
37. Eckman MH, Levine HJ, Salem DN, Pauker SG. Making decisions about antithrombotic therapy in heart disease: Decision analytic and cost-effectiveness issues. Chest 1998;114:699S-714S
38. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11
39. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-2570
40. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767
41. Amarenco P, Bogousslavsky J, Callahan III A, et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators. high-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355(6):549-559
42. Sacco RL, Diener HC, Yusuf S, et al. PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359(12):1238-1251
43. Sorensen SV, Dewilde S, Singer DE, et al. Cost-effectiveness of warfarin: Trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J 2009;157:1064-1073
44. Available from: Http://guidance.nice.org. uk/TA210 [Last accessed 11 November 2011]
45. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706
46. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thromb Haemost 2011;105:908-919
47. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151